TY - JOUR
T1 - Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock
AU - Damluji, Abdulla A.
AU - Tehrani, Behnam
AU - Sinha, Shashank S.
AU - Samsky, Marc D.
AU - Henry, Timothy D.
AU - Thiele, Holger
AU - West, Nick E.J.
AU - Senatore, Fortunato F.
AU - Truesdell, Alexander G.
AU - Dangas, George D.
AU - Smilowitz, Nathaniel R.
AU - Amin, Amit P.
AU - deVore, Adam D.
AU - Moazami, Nader
AU - Cigarroa, Joaquin E.
AU - Rao, Sunil V.
AU - Krucoff, Mitchell W.
AU - Morrow, David A.
AU - Gilchrist, Ian C.
N1 - Funding Information:
Dr Damluji was supported by research funding from the Pepper Scholars Program of the Johns Hopkins University Claude D. Pepper Older Americans Independence Center funded by the National Institute on Aging (P30-AG021334) and mentored patient-oriented research career development award from the National Heart, Lung, and Blood Institute (NHLBI) (K23-HL153771-01). Dr Samsky received salary support from a National Institutes of Health T32 Training Grant (HL069749). Dr Smilowitz was supported, in part, by the NHLBI (Award Number K23HL150315); and has served on the advisory board for Abbott Vascular. Dr Tehrani has served as a consultant for Medtronic; and on the advisory board for Abbott Medical and Retriever Medical. Dr West is an employee of Abbott Vascular. Dr Moazami has served on an independent provider quality panel for Medtronic related to safety evaluation of mechanical support devices. Dr Truesdell has served as a consultant and a speaker for Abiomed. Dr Dangas has received research grant support from Mt. Sinai Hospital, Abbott Vascular, Boston Scientific, Medtronic, and Biotronik. Dr Amin has received research grant support from Terumo. Dr Rao has received institutional research funding from Bayer, the NHLBI, and the American College of Cardiology. Dr Krucoff has received consulting and research grants support from Edwards, Medtronic, Abbott Vascular, Abiomed, Cardiovascular Systems, Inc, Boston Scientific, Bard, Cook Medical, and Terumo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The content and opinions expressed in this manuscript do not necessarily reflect guidance or policies of the U.S. Food and Drug Administration.
Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/10/24
Y1 - 2022/10/24
N2 - In the United States, the frequency of using percutaneous mechanical circulatory support devices for acute myocardial infarction complicated by cardiogenic shock is increasing. These devices require large-bore vascular access to provide left, right, or biventricular cardiac support, frequently under urgent/emergent circumstances. Significant technical and logistical variability exists in device insertion, care, and removal in the cardiac catheterization laboratory and in the cardiac intensive care unit. This variability in practice may contribute to adverse outcomes observed in centers that receive patients with cardiogenic shock, who are at higher risk for circulatory insufficiency, venous stasis, bleeding, and arterial hypoperfusion. In this position statement, we aim to: 1) describe the public health impact of bleeding and vascular complications in cardiogenic shock; 2) highlight knowledge gaps for vascular safety and provide a roadmap for a regulatory perspective necessary for advancing the field; 3) propose a minimum core set of process elements, or “vascular safety bundle”; and 4) develop a possible study design for a pragmatic trial platform to evaluate which structured approach to vascular access drives most benefit and prevents vascular and bleeding complications in practice.
AB - In the United States, the frequency of using percutaneous mechanical circulatory support devices for acute myocardial infarction complicated by cardiogenic shock is increasing. These devices require large-bore vascular access to provide left, right, or biventricular cardiac support, frequently under urgent/emergent circumstances. Significant technical and logistical variability exists in device insertion, care, and removal in the cardiac catheterization laboratory and in the cardiac intensive care unit. This variability in practice may contribute to adverse outcomes observed in centers that receive patients with cardiogenic shock, who are at higher risk for circulatory insufficiency, venous stasis, bleeding, and arterial hypoperfusion. In this position statement, we aim to: 1) describe the public health impact of bleeding and vascular complications in cardiogenic shock; 2) highlight knowledge gaps for vascular safety and provide a roadmap for a regulatory perspective necessary for advancing the field; 3) propose a minimum core set of process elements, or “vascular safety bundle”; and 4) develop a possible study design for a pragmatic trial platform to evaluate which structured approach to vascular access drives most benefit and prevents vascular and bleeding complications in practice.
KW - cardiogenic
KW - complications
KW - myocardial infarction
KW - shock
KW - vascular access devices
UR - http://www.scopus.com/inward/record.url?scp=85139355529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139355529&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2022.08.041
DO - 10.1016/j.jcin.2022.08.041
M3 - Review article
C2 - 36265932
AN - SCOPUS:85139355529
SN - 1936-8798
VL - 15
SP - 2003
EP - 2019
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 20
ER -